Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 17, 2026 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported financial results for the three and nine months ended September 30, 2026, and provided an update on recent business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Purple Biotech today has a focused set of assets: the CAPTN-3 platform, its lead candidate IM1240, and a second candidate, IM1305. That foundation was built under Gil Efron as Chief Executive Officer," said Isaac Israel, Interim Chief Executive Officer of Purple Biotech. "My first priority is to bring IM1240 into a first-in-human study. What we believe sets CAPTN-3 apart is that its antibodies are designed to engage both T cells and NK cells against the tumor and to confine that activity to the tumor microenvironment. Many patients with advanced solid tumors do not respond to today’s immunotherapies, or relapse after an initial response. Those are the patients we are working for."

"Alongside our preparation of an IND application for IM1240, we continue to advance additional work on the platform. IM1240 data in treatment-resistant human tumor models will be presented this week in a plenary session at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium. Separately, we plan to report new preclinical data on IM1305, our second candidate, in the near term," Mr. Israel added. "As we previously reported, we are also bringing artificial intelligence into our antibody development. In our collaboration with Converge Bio, we are applying generative artificial intelligence to the design and optimization of our tri-specific antibodies, and we expect to provide an update on that work shortly. We believe artificial intelligence has the potential to make significant parts of drug development more efficient, and we intend to extend its use across the Company, with attention to data security and privacy."

Business Update:

IM1240 abstract selected for a plenary oral presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium

Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as the pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented by Amir Horowitz, Ph.D., of the Icahn School of Medicine at Mount Sinai, in Plenary Session 7: Proffered Papers on Friday, November 20, 2026, at 15:00 CET (Abstract ENA26-0137).
U.S. patent granted for the CAPTN-3 platform

In September 2026, we received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application covering tri-specific antibody constructs and methods of use, and the patent was subsequently granted. The patent further strengthens our intellectual property portfolio and supports the development and partnering potential of the CAPTN-3 platform.
Financial Results for the Three Months Ended September 30, 2026

Research and Development Expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.6 million for the same period in 2025, representing a decrease of $0.2 million. The decrease was primarily attributable to lower Chemistry, Manufacturing and Controls (CMC) and patent expenses.

General and Administrative Expenses were $0.7 million for the three months ended September 30, 2026, compared to $0.8 million for the corresponding period in 2025. The decrease was mainly due to lower consulting and non-cash bonus expenses.

Operating Loss was $1.1 million for the three months ended September 30, 2026, compared to $1.4 million for the corresponding period in 2025, representing a decrease of $0.3 million. The decrease was primarily attributable to lower research and development and general and administrative expenses.

Adjusted Operating Loss (as reconciled below) was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025.

Finance Income, Net was $0.1 million for the three months ended September 30, 2026, and for the corresponding period in 2025.

Net Loss was $1.0 million for the three months ended September 30, 2026, compared to $1.3 million for the corresponding period in 2025. The decrease was primarily attributable to lower operating expenses, and, to a lesser extent, to higher non-cash finance income resulting from changes in the fair value of outstanding warrants.

Adjusted Net Loss (as reconciled below) was $1.1 million for the three months ended September 30, 2026, compared to $1.2 million for the same period in 2025. Adjusted net loss excludes non-cash share-based compensation expenses and finance income or expenses resulting from changes in the fair value of outstanding warrants.

As of September 30, 2026, we had cash, cash equivalents and short-term deposits of $5.1 million, which, based on current management estimates and our current operating plan, are expected to provide us with a cash runway through late-2027.

Non-IFRS Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with International Financial Reporting Standards ("IFRS"), including adjusted operating loss and adjusted net loss. These non-IFRS measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similar measures presented by other companies. Adjusted operating loss and adjusted net loss adjust for non-cash share-based compensation expenses, and adjusted net loss also adjusts for finance income or expenses resulting from changes in the fair value of outstanding warrants. The Company’s management and board of directors utilize these non-IFRS financial measures to evaluate its performance. The Company provides these non-IFRS measures of its performance to investors because management believes that these non-IFRS financial measures, when viewed with its results under IFRS and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-IFRS measures are not measures of financial performance under IFRS and, accordingly, should not be considered in isolation or as alternatives to IFRS measures as indicators of operating performance. Further, these non-IFRS measures should not be considered measures of the Company’s liquidity. A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

(Press release, Purple Biotech, NOV 17, 2026, View Source [SID1234674902])